Compare Main Street Capital Corporation (MAIN) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Medtronic PLC — how do they compare? Main Street Capital Corporation trades at $54.47 (market cap $5.07B), while Medtronic PLC trades at $87.9 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 21.6× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.87%). Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Medtronic PLC for 63 Days on average.
| MAIN | MDT | |
|---|---|---|
Market Cap | $5.07B | $109.38B |
Volume | 685,683 | 55,890,185 |
Sector | Financials | Health |
52-Week High | $64.60 | $105.35 |
52-Week Low | $49.63 | $73.75 |
Typical Hold Time | 88 Days | 63 Days |
Enterprise Value | $7.51B | $128.71B |
Dividend Yield | 5.87% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with an 80.77% net income margin. Recent news highlights MAIN's status as a top-tier BDC with a well-covered monthly dividend, though some analysts cite valuation concerns amid rising Treasury yields.
Outlook remains cautiously optimistic given MAIN's robust fundamentals and dividend track record, but near-term headwinds include earnings volatility and premium valuation risks. The stock offers income appeal with a 7.9%+ yield, yet investors face pressure from technical weakness and macroeconomic sensitivity.
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
